3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Carcinoma, Hepatocellular
15
Small Cell Lung Carcinoma
11
Triple Negative Breast Neoplasms
9
Neoplasms
8
Colorectal Neoplasms
6
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Lung Neoplasms
5
Carcinoma, Renal Cell
5
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Venous Thrombosis
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Prostatic Neoplasms, Castration-Resistant
1
Peritoneal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non-Small-Cell Lung
1
Interventions
Letrozole
5
Paclitaxel
4
atamestane
3
Toremifene
3
Tamoxifen
3
Cyclophosphamide
3
Estrogen Receptor Modulators
2
Epirubicin
2
Doxorubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Aromatase Inhibitors
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
pertuzumab
1
ferric carboxymaltose
1
atezolizumab
1
Vinorelbine
1
Trastuzumab
1
TP protocol
1
Surgical Procedures, Operative
1
Radiotherapy
1
Medroxyprogesterone
1
Fulvestrant
1
Fluorouracil
1
Estrogens, Conjugated (USP)
1
Cisplatin
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Ductal, Breast
×
atezolizumab
×
Clear all
NCT02620280
2024-03-06
NeoTRIPaPDL1
Fondazione Michelangelo
Phase 3
Completed
278 enrolled